Abstract

Differentiating the invasiveness of ground-glass nodules (GGN) is clinically important, and several institutions have attempted to develop their own solutions by using computed tomography images. The purpose of this study is to evaluate Computer-Aided Analysis of Risk Yield (CANARY), a validated virtual biopsy and risk-stratification machine-learning tool for lung adenocarcinomas, in a Korean patient population. To this end, a total of 380 GGNs from 360 patients who underwent pulmonary resection in a single institution were reviewed. Based on the Score Indicative of Lung Cancer Aggression (SILA), a quantitative indicator of CANARY analysis results, all of the GGNs were classified as “indolent” (atypical adenomatous hyperplasia, adenocarcinomas in situ, or minimally invasive adenocarcinoma) or “invasive” (invasive adenocarcinoma) and compared with the pathology reports. By considering the possibility of uneven class distribution, statistical analysis was performed on the 1) entire cohort and 2) randomly extracted six sets of class-balanced samples. For each trial, the optimal cutoff SILA was obtained from the receiver operating characteristic curve. The classification results were evaluated using several binary classification metrics. Of a total of 380 GGNs, the mean SILA for 65 (17.1%) indolent and 315 (82.9%) invasive lesions were 0.195±0.124 and 0.391±0.208 (p < 0.0001). The area under the curve (AUC) of each trial was 0.814 and 0.809, with an optimal threshold SILA of 0.229 for both. The macro F1-score and geometric mean were found to be 0.675 and 0.745 for the entire cohort, while both scored 0.741 in the class-equalized dataset. From these results, CANARY could be confirmed acceptable in classifying GGN for Korean patients after the cutoff SILA was calibrated. We found that adjusting the cutoff SILA is needed to use CANARY in other countries or races, and geometric mean could be more objective than F1-score or AUC in the binary classification of imbalanced data.

Highlights

  • Lung cancer is one of the most common causes of cancer-related deaths throughout the world, and lung adenocarcinoma is the most common histologic subtype of lung cancer [1]

  • According to the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC,ATS,ERS) guidelines, lung adenocarcinomas can be classified as atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma (IA), depending on the size of the lesion and the presence of invasive components on the pathological analysis [2]

  • We evaluated the versatility of Computer-Aided Nodule Assessment and Risk Yield (CANARY) by applying Korean patients

Read more

Summary

Introduction

Lung cancer is one of the most common causes of cancer-related deaths throughout the world, and lung adenocarcinoma is the most common histologic subtype of lung cancer [1]. According to the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC,ATS,ERS) guidelines, lung adenocarcinomas can be classified as atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma (IA), depending on the size of the lesion and the presence of invasive components on the pathological analysis [2]. These classifications are well correlated to survival rates; disease-free survival in early-stage AIS and MIA patients is close to 100% [3], while disease-free survival in IA patients is 60–70%. In this study, we evaluated the versatility and performance of CANARY in indolent-and-invasive separation by applying it to data collected from Korean patients and found that it provided reliable performance in distinguishing between indolent and invasive nodules from the chest CT images of the patients

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call